These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48 related articles for article (PubMed ID: 2917450)
21. [Controlled study of the antihypertensive efficacy of the combination of nadolol and bendroflumethiazide with respect to nadolol alone and placebo]. Cherchi A; Sau F; Mercuro G; Seguro C; Lai O Clin Ter; 1985 May; 113(4):301-6. PubMed ID: 3893868 [No Abstract] [Full Text] [Related]
22. [Three antipsychotic drugs in the treatment of schizophrenia--a controlled and double-blind study]. Yang WJ Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1988 Oct; 21(5):277-80, 318-9. PubMed ID: 3069383 [No Abstract] [Full Text] [Related]
23. Clinical response of aggressive schizophrenics to oral tryptophan. Morand C; Young SN; Ervin FR Biol Psychiatry; 1983 May; 18(5):575-8. PubMed ID: 6860730 [No Abstract] [Full Text] [Related]
24. Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial. Sival RC; Haffmans PM; Jansen PA; Duursma SA; Eikelenboom P Int J Geriatr Psychiatry; 2002 Jun; 17(6):579-85. PubMed ID: 12112183 [TBL] [Abstract][Full Text] [Related]
25. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Citrome L; Shope CB; Nolan KA; Czobor P; Volavka J Int Clin Psychopharmacol; 2007 Nov; 22(6):356-62. PubMed ID: 17917554 [TBL] [Abstract][Full Text] [Related]
26. Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients. Barkan T; Peled A; Modai I; Barak P; Weizman A; Rehavi M Eur Neuropsychopharmacol; 2006 Dec; 16(8):572-9. PubMed ID: 16713194 [TBL] [Abstract][Full Text] [Related]
27. [Clinical evaluation of nadolol in coronary disease]. Krotkiewski A; Zatorski A; Jarecki M; Ruszkowski J; Szelemetko J Pol Tyg Lek; 1980 Jun; 35(22):833-6. PubMed ID: 6106925 [No Abstract] [Full Text] [Related]
28. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. Greendyke RM; Kanter DR J Clin Psychiatry; 1986 Aug; 47(8):423-6. PubMed ID: 3525523 [TBL] [Abstract][Full Text] [Related]
29. Nadolol in the treatment of central serous retinopathy. Browning DJ Am J Ophthalmol; 1993 Dec; 116(6):770-1. PubMed ID: 8250086 [No Abstract] [Full Text] [Related]
30. A double blind controlled study of ECT vs chlorpromazine in schizophrenia. Bagadia VN; Abhyankar RR; Doshi J; Pradhan PV; Shah LP J Assoc Physicians India; 1983 Oct; 31(10):637-40. PubMed ID: 6671932 [No Abstract] [Full Text] [Related]
31. Effect of nadolol on flushing reactions in rosacea. Wilkin JK J Am Acad Dermatol; 1989 Feb; 20(2 Pt 1):202-5. PubMed ID: 2521641 [TBL] [Abstract][Full Text] [Related]
33. The measurement of aggressive behavior: reflections on the use of the Overt Aggression Scale and the Modified Overt Aggression Scale. Ratey JJ; Gutheil CM J Neuropsychiatry Clin Neurosci; 1991; 3(2):S57-60. PubMed ID: 1821223 [No Abstract] [Full Text] [Related]
34. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Arango C; Bernardo M Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402 [TBL] [Abstract][Full Text] [Related]
35. Beta-adrenergic blockers for aggressive behavior in schizophrenia. Am J Psychiatry; 1987 Apr; 144(4):538-9. PubMed ID: 2882699 [No Abstract] [Full Text] [Related]
36. The treatment of impulsive and aggressive behavior with nadolol. Polakoff SA; Sorgi PJ; Ratey JJ J Clin Psychopharmacol; 1986 Apr; 6(2):125-6. PubMed ID: 3700702 [No Abstract] [Full Text] [Related]
37. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. Nasrallah HA; Tandon R J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142 [TBL] [Abstract][Full Text] [Related]
38. Nadolol in the treatment of aggressive behavior associated with schizophrenia. Ritrovato CA; Weber SS; Dufresne RL Clin Pharm; 1989 Feb; 8(2):132-5. PubMed ID: 2917450 [No Abstract] [Full Text] [Related]